Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005659700
Wed, 23.03.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 23 March 2022. Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with the Canadian biotech company Alpha-9 Theranostics Inc. (Alpha-9) a clinical supply agreement for Eckert & Ziegler's medical radioisotope Lutetium-177 (non-carrier-added 177Lu). The isotope will be used for the clinical development of Alpha-9's investigatio [ … ]
Tue, 22.03.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 22 March 2022. Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have extended their long-term supply agreement for the use of yttrium-90 in Sirtex microspheres for the treatment of liver cancer to the Chinese market. The agreement guarantees EZAG a significant share of the growing global demand for Y90-based m [ … ]
Wed, 09.02.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 9 February 2022. Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with Telix Pharmaceuticals Limited (ASX:TLX, Telix) a comprehensive global supply agreement for Eckert & Ziegler's therapeutic radioisotope Lutetium-177 (non-carrier-added 177Lu). The radiopharmaceutical will be used to advance Telix's portfolio of Molecularl [ … ]
Mon, 10.01.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 10 January 2022. Eckert & Ziegler Radiopharma GmbH (EZR), the radiopharmaceutical production arm of Eckert & Ziegler, has signed a joint venture and exclusive long-term supply agreements for Ytterbium-176 with Atom Mines LLC, an innovative producer of enriched Ytterbium isotopes and a subsidiary of the non-profit Pointsman Foundatio [ … ]
Mon, 03.01.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 3 January 2022. Eckert & Ziegler has acquired 100% of the shares of Argentinian nuclear medicine specialist Tecnonuclear S. A., a manufacturer of Technetium-99 generators and a portfolio of related biomolecules. These so-called "cold kits" function as vectors for the in-vivo delivery of Technetium-99 to more specific biological targets [ … ]
Tue, 30.11.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin / Toronto, 30 November 2021. Eckert & Ziegler Group is pleased to announce their partnership today with the Canadian Molecular Imaging Probe Consortium (CanProbe), a leader in the advancement and commercialization of novel radiopharmaceuticals to better serve patients and with the University Health Network (UHN), Canada's largest health [ … ]
Thu, 18.11.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 18 November 2021. Eckert & Ziegler Radiopharma GmbH has received approval for its pharmaceutical 68Ge/68Ga generator GalliaPharm(R) from the Brazilian health authority ANVISA. GalliaPharm(R) is thus the first and currently the only pharmaceutical gallium generator approved in Brazil.
"The approval strengthens our market position in Bra [ … ]
Fri, 12.11.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 12 November 2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX) announced that the Clinical Trial Notification (CTN) of a joint clinical study with Novartis Pharma K.K. (Japan) was accepted by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for 68Ga-PSMA-11, an investigational radioligand imaging agent and 177Lu-PSMA-617, [ … ]
Tue, 09.11.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 9 November 2021. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), achieved a record result in the first nine months of 2021 with a net profit of € 29.2 million or € 1.41 per share. By the end of September, earnings had thus already exceeded those of the entire previous year by € 11.6 million or 65%. Adjusted [ … ]
Fri, 05.11.2021
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 5 November 2021. Eckert & Ziegler AG (ISIN DE0005659700), a global specialist for isotope applications in medicine and industry has acquired an approximately 7,000 m² property with an expansion option for the building of its Chinese production facility in Jintan (PR China). The purchase was made through a public tender process. The loca [ … ]